This mechanism of action achieves comprehensive inhibition at different stages of NLRP3 inflammasome activation, making it a promising candidate for the management of AP, peritonitis, and other inflammasome-associated diseases [41]. This evidence concerns the gene NLRP3 and peritonitis.